THERAPY DOSSIER · th-c378d2029c01

Ciclopirox olamine

Drug · Iron chelating agent; aluminium chelating agent (trivalent metal cation chelation, inhibiting metal-dependent peroxide-degrading enzymes)

Not approved Suggest a correction

Evidence & regulatory context

Mechanism: Iron chelating agent; aluminium chelating agent (trivalent metal cation chelation, inhibiting metal-dependent peroxide-degrading enzymes)
Target: CHEMBL2363058; CHEMBL2366381
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL242580 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: Ciclopirox olamine; Batrafen; Dafnegin; HOE-296; NSC-336278; Mycoster; Ciclopirox (parent CHEMBL1413)
Note: Not recorded

Clinical trials 10

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05809297 ↗PHASE4unknown

Diode Laser and Photodynamic Therapy Versus Ciclopirox Hydroxypropyl Chitosan

Onychomycosis

Enrolment: 26 · Results not recorded

NCT02004860 ↗PHASE3completed

Tacrolimus Ointment Interest (PROTOPIC) in the Maintenance Treatment of Severe Seborrheic Dermatitis on Adult Face

Severe Seborrheic Dermatitis

Enrolment: 120 · Results not recorded

NCT02961634 ↗PHASE3unknown

Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis

Onychomycosis

Enrolment: 46 · Results not recorded

NCT02866032 ↗PHASE3completed

Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis

Distal Subungual Onychomycosis

Enrolment: 452 · Results not recorded

NCT00802672 ↗PHASE3completed

Safety and Clinical Equivalence of a Generic Ciclopirox Olamine Cream to Ciclopirox Cream 0.77% in the Treatment of Tinea Pedis

Tinea Pedis

Enrolment: 561 · Results not recorded

NCT02644551 ↗PHASE2unknown

The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis

Onychomycosis

Enrolment: 120 · Results not recorded

NCT00990587 ↗PHASE1completed

Phase 1 Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy

Hematologic Malignancy · Acute Myeloid Leukemia · Myelodysplasia

Enrolment: 20 · Results not recorded

NCT00127868 ↗NAcompleted

Selenium Sulfide 1%, Ketoconazole 2% and Ciclopirox 1% Shampoo as Adjunctive Treatments for Tinea Capitis in Children

Tinea Capitis

Enrolment: 47 · Results not recorded

NCT00382330 ↗NAwithdrawn

Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox

Vulvar Cancer

Enrolment: 0 · Results not recorded

NCT06485050 ↗NAunknown

Photodynamic Therapy as Adjuvant Therapy to Topical Antifungal Treatments for Onychomycosis in Patients With Diabetes

Onychomycosis of Toenail · Diabetic Foot

Enrolment: 10 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32140390 ↗2019Reported benefit

Repurposing antimycotic ciclopirox olamine as a promising anti-ischemic stroke agent.

RatIschaemia-reperfusionCerebral (MCAO/stroke)Sprague-DawleyMalen = 471 rats enrolled, 307 analysed, 164 excluded for death or…Intravenous1, 3 and 10 mg/kg in dose ranging, with 3 mg/kg selectedImmediately after monofilament withdrawal at reperfusion; a delayed cohort rece…

Model: Transient middle cerebral artery occlusion for 2 hours followed by reperfusion, intraluminal monofilament, chloral hydrate 400 mg/kg anaesthesia; a separate cohort had permanent occlusion without reperfusion

Ciclopirox olamine reduced infarct volume by 13.1%, 22.5% and 11.9% at 1, 3 and 10 mg/kg, improved neurological deficit and brain oedema, and improved rotarod performance with multiple dosing better than single dosing. It reduced neuronal loss, apoptosis, astrocyte activation, cytokines and blood b…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…